Please assess the completion status of the following clinical trial:

Trial Title: Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. To have been diagnosed MS Remittent Recurrent according to Mc Donald 20052 criteria.~2. To have an EDSS between 0 and 5 before the relapse.~3. The symptoms have begun after at least one month of previous stability.~4. The symptoms have started maximum 15 days before the inclusion.~5. The patient is capable of having an adequate communication with the investigator and to carry out with the clinical trial requisites.~6. To be or not to be with allowed immunomodulatory therapy (IFN-B /AG).~7. To be capable and to be willing to ingest the medication.~Exclusion Criteria:~1. First inflammatory neurological episode (relapse).~2. Multiple sclerosis secondary progressive or primary progressive.~3. The symptoms have gone on for less than 24 hours.~4. To be in treatment or have been treated with corticoids during the three months before.~5. Patients in treatment with immunosuppressors (azathioprine, mitoxantrone, ciclofosfamide...)~6. Pregnancy or breastfeeding or women in fertile age who don't use contraceptives measurements.~7. Illnesses with contraindication treatment with corticoids.~8. Antecedents of serious adverse effects or hypersensitive to related study medication.~9. Patients who wouldn´t be able to perform periodic RMN explorations, patients who are not collaborative or who need anesthesia.~10. Patients with intolerance to lactose.~11. Patients with allergy to contrast used in RMN.~12. Patients with chronic kidney disease.~13. Patients in treatment with natalizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
- 2 (Type: EXPERIMENTAL): methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered

Based on this trial design, predict the completion outcome and termination type (if applicable).